Hepatitis C
New hepatitis C combination treatment effective in HIV coinfected patients
Patients with both hepatitis C virus and HIV responded well to daclatasvir combined with sofosbuvir in a study.
Source: National Institute of Allergy and Infectious Diseases (NIAID)
Infection with HIV (pictured), concurrently with hepatitis C virus, can speed up the onset of liver disease
Worldwide, hepatitis C virus (HCV) infection affects up to a quarter of people with HIV type 1 (HIV-1), accelerating the onset of liver disease. Now, results of an open-label study suggest that treatment with the NS5A inhibitor daclatasvir, together with the NS5B inhibitor sofosbuvir, is effective against HCV in HIV-coinfected patients.
The ALLY-2 trial, funded by Bristol-Myers Squibb and published in The New England Journal of Medicine (online, 21 July 2015[1]), involved 151 previously untreated patients with HCV genotypes 1–4 and HIV-1 infection who were given daclatasvir 60mg plus sofosbuvir 400mg daily for either 8 weeks or 12 weeks. The study also involved 52 previously treated patients who were given 12 weeks of therapy at the same doses.
In treatment-naïve patients, sustained virologic response (SVR) rates for HCV were 97.0% with 12 weeks’ treatment and 76.0% with 8 weeks’ treatment. In previously treated patients, SVR was 98.1% after 12 weeks.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069093
Recommended from Pharmaceutical Press
- Previous
- Next
BNF and British National Formulary for Children
Now available as a 1 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.
£138.50Buy now
BNF and British National Formulary for Children
Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.
£262.50Buy now
Pharmaceutical Toxicology
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.
£40.00Buy now
Sport and Exercise Medicine for Pharmacists
All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.
£27.00Buy now
Further MCQs in Pharmacy Practice
Further MCQs in Pharmacy Practice contains 600 practice-oriented pharmacy exam questions. Includes both open- and closed-book sections.
£30.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.